Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Kim, Won Young ^a   Moon, Jae Young ^a,b   Huh, Jin Won ^a   Choi, Sang Ho ^a   Lim, Chae Man ^a   Koh, Younsuck ^a   Chong, Yong Pil ^a   Hong, Sang Bum ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; COLISTIN; DOXYCYCLINE; MINOCYCLINE; RIFAMPICIN; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT PNEUMONIA; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY RATE; MULTIDRUG RESISTANT PNEUMONIA; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; RISK FACTOR; TREATMENT OUTCOME; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPLICATION; CRITICAL ILLNESS; DRUG EFFECTS; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84962495730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150642     Document Type: Article

References (34)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-582. doi: 10.1128/CMR.00058-07 PMID: 18625687
2. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. CritCare. 2006;10(2):R48. PMID: 16563184
3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(10):3471-3484. PMID: 17646423
4. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-1341. PMID: 15825037
5. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistancetocolistin in multidrug-resistant Acinetobacterbaumannii. Antimicrob Agents Chemother. 2006;50(9):2946-2950. PMID: 16940086
6. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother. 2008;52(1):351-352. PMID: 17954699
7. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879-884. doi: 10.1093/cid/cir611 PMID: 21900484
8. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341-353. PMID: 16080072
9. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005;5:88. PMID: 16236177
10. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline forthe treatment of multidrugresistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008;62(1):45-55. doi: 10.1093/jac/dkn165 PMID: 18436554
11. Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother. 2009;64(4):837-839. doi: 10.1093/jac/dkp301 PMID: 19696049
12. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacterbaumannii. Pharmacotherapy. 2007;27(7):980-987. PMID: 17594203
13. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008;46(4):567-570. doi: 10.1086/526775 PMID: 18199038
14. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi: 10.1111/j. 1469-0691.2011.03570.x PMID: 21793988
15. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsisrelated Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710. PMID: 8844239
16. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991;143(5 Pt 1):1121-1129. PMID: 2024824
17. Kim T, Chong YP, Park SY, Jeon MH, Choo EJ, Chung JW, et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea. Diagn Microbiol Infect Dis. 2014;78(4):457-461. doi: 10.1016/j.diagmicrobio.2013. 08.011 PMID: 24462178
18. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis. 2010;51(11):1238-1244. doi: 10.1086/657242 PMID: 20973727
19. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactamvs.colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56(6):432-436. doi: 10.1016/j.jinf.2008.04.002 PMID: 18501431
20. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. (M100-S22). Wayne, PA: CLSI; 2012.
21. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecyclinebased versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistantAcinetobacterbaumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102. doi: 10.1186/1471-2334-14-102 PMID: 24564226
22. Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study. Crit Care Med. 2015;43(6):1194-1204. doi: 10.1097/CCM.0000000000000933 PMID: 25793437
23. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control. 2012;40(10):983-987. doi: 10.1016/j.ajic.2011.12. 014 PMID: 22440526
24. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis. 2013;32(9):1211-1120. doi: 10.1007/s10096-013-1870-4 PMID: 23553594
25. Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, Bou G, Tomas M, Garnacho-Montero J, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother. 2014;69(11):3119-3126. doi: 10.1093/jac/dku233 PMID: 24970742
26. Marchaim D, Navon-Venezia S, Schwartz D, Tarabeia J, Fefer I, Schwaber MJ, et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol. 2007;45(5):1551-1555. PMID: 17314222
27. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009;34(1):101-102. doi: 10.1016/j.ijantimicag.2009.01.015 PMID: 19278835
28. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140-151. doi: 10.1016/j.diagmicrobio.2010.05.012 PMID: 20846586
29. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756-1762. doi: 10.1128/AAC.01232-12 PMID: 23357775
30. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1311-1322. doi: 10.1007/s10096-014-2070-6 PMID: 24532009
31. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7(12):e52349. doi: 10.1371/journal.pone.0052349 PMID: 23285002
32. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220-229. PMID: 15616299
33. Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, et al. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis. 2013;45(4):315-319. doi: 10.3109/00365548.2012.732705 PMID: 23113680
34. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59(1):128-131. PMID: 17082201